Unii-o0p4I5851i

Unii-o0p4I5851i Struktur
139563-29-4
CAS-Nr.
139563-29-4
Englisch Name:
Unii-o0p4I5851i
Synonyma:
Unii-o0p4I5851i;Lurasidone Impurity E;Lurasidone hydrochloride
CBNumber:
CB02493594
Summenformel:
C28H37ClN4O2S
Molgewicht:
529.13698
MOL-Datei:
139563-29-4.mol

Unii-o0p4I5851i Eigenschaften

Schmelzpunkt:
>250°C (dec.)
storage temp. 
Refrigerator
Löslichkeit
Chloroform (Very Slightly, Sonicated), Methanol (Slightly, Heated)
Aggregatzustand
Solid
Farbe
White to Off-White
CAS Datenbank
139563-29-4

Sicherheit

Unii-o0p4I5851i Chemische Eigenschaften,Einsatz,Produktion Methoden

Clinical Use

Lurasidone hydrochloride is an antipsychotic developed by the Japanese firm Dainippon Sumitomo and approved by the U.S. FDA for the treatment of schizophrenia. The compound exhibits significant antagonist effects at the D2, 5-HT2A, and 5-HT7 receptors which are linked to learning and cognition. In contrast to available antipsychotics, lurasidone lacks anticholinergic side effects, giving it an improved safety profile against existing treatments.139 The drug is manufactured under the trade name Latuda and possesses a linear molecular topology which can be subdivided into three regions: a piperazine benzothiazole, a [2.2.1]-bicycloheptane fused succinimide, and a trans-1,2 disubstituted cyclohexane.

Synthese

The large scale preparation of lurasidone involves an interesting ring-opening alkylation reaction of a spirocyclic tetralkyl ammonium salt to produce the 1,2-trans-substituted cyclohexane subunit. The synthesis commenced with the bismesylation of commercially available diol 177, which proceeded in high yield to give disulfone 178. This bis-electrophile underwent dialkylation with commercially available piperazine 179 under basic conditions, giving rise to ammonium species 180, isolated in 80% yield as the mono-mesylate salt. This compound was immediately subjected to alkylative conditions in the presence of commercially available succinimide 181 to provide lurasidone in 94% yield from 180, and lurasidone hydrochloride (XVI) was achieved by subsequent salt formation procedure.

Synthesis_139563-29-4

Unii-o0p4I5851i Upstream-Materialien And Downstream Produkte

Upstream-Materialien

Downstream Produkte


Unii-o0p4I5851i Anbieter Lieferant Produzent Hersteller Vertrieb Händler.

Global( 45)Lieferanten
Firmenname Telefon E-Mail Land Produktkatalog Edge Rate
Sinoway Industrial co., ltd.
0592-5800732; +8613806035118
xie@china-sinoway.com China 992 58
sgtlifesciences pvt ltd
+8617013299288
dj@sgtlifesciences.com China 12382 58
Shandong Risen-Sun Pharmaceutical Co., Ltd
+86-15552509998 +86-15621883869
liutf@jewim.com.cn China 251 58
Suzhou ARTK Medchem Co., Ltd.
+86-512-68323967 +86-18015559028
sales1@artkmedchem.com China 39009 58
Shenzhen SUNGENING Bio-Medical Co., Ltd. 0755-28967200 13631290199
wxf@sungening.com China 9507 60
Conier Chem & Pharma Limited 13368167990
sales@conier.com China 2809 58
Shenzhen Polymeri Biochemical Technology Co., Ltd. +86-400-002-6226 13028896684
sales@rrkchem.com China 55954 58
Cato Research Chemicals Inc. 020-81215950 4000-868-328
customer@uwalab.com United States 10413 58
Shaanxi Dideu Medichem Co. Ltd 029-61856359 18690052321
1027@dideu.com China 10011 58

  • Lurasidone hydrochloride
  • Unii-o0p4I5851i
  • Lurasidone Impurity E
  • 139563-29-4
Copyright 2019 © ChemicalBook. All rights reserved